e United States, today announced the selection of Foundation Medicine as its preferred partner for comprehensive cancer genomic profiling services. Foundation Medicine's clinical products, FoundationOneTM for solid tumors and FoundationOneTM Heme for hematologic malignancies, sarcomas and pediatric cancers, each provi

16. As the result of Foundation Medicine and Novartis' pilot program established in January 2011 and an expanded three-year agreement in June 2012, Foundation Medicine's comprehensive genomic profiling has generated clinically relevant data and is now regularly used in many of Novartis' oncology clinical trials. Thi